Tag Archives: ATEC

Top Bank Stocks To Watch For 2018

We all know financial stocks have gone through the roof since President Trump’s win. So the question becomes: what do we do with these companies now?

There’s no one answer for every financial stock, of course.

Some are still great, undervalued buys—but there are two that have gotten grossly overvalued and should be avoided, or sold if you hold them. (Below, I’ll reveal 3 better high-yield stocks to buy instead.)

These 2 Financials Are Headed for Trouble

Bank of America Corp (BAC) is the first bank on my hit list.

A Breathtaking Rise

After spending most of 2016 in the red, BAC has soared more than 37% in three months. Nothing much has changed at the bank; it’s just riding a wave of euphoria as investors bet that Trump’s America will mean higher interest rates and fewer regulations, driving up BAC’s earnings.

Top Bank Stocks To Watch For 2018: Alphatec Holdings, Inc.(ATEC)

Advisors’ Opinion:

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha)
    Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha)
    Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period.
    Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share.
    Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement.
    Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share.
    Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76.
    QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share.
    Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering.
    Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston
  • [By Lisa Levin]

    Shares of Alphatec Holdings Inc (NASDAQ: ATEC) were down around 25 percent to $2.00 as the company reported an $18.9 million private placement.

    Heat Biologics Inc (NASDAQ: HTBX) was down, falling around 15 percent to $0.872. Heat Biologics priced its 5 million share offering at $0.80 per share.

Top Bank Stocks To Watch For 2018: Panasonic Corporation (PCRFY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Clean Technica reported on September 1 that “Sony is entering the EV battery manufacturing industry”. And “considering that electric vehicle batteries are going to be the main supply bottleneck for the upcoming auto market’s embrace of EVs, the entry of Sony into the field is very notable. Most of the other manufacturers (Panasonic (OTCPK:PCRFY), LG Chem (OTC:LGCLF), etc.) already have more or less all of their production capacity locked up for the coming years – meaning there’s not much left for the auto manufacturers that are running behind, thereby limiting potential EV sales for the firms in question. Sony’s (NYSE:SNE) entry into the field should open things up a bit more”. Certainly a good move by Sony and helpful for the EV companies that will find themselves in need of batteries, and limited availability, should EVs reach 10% by 2020.

  • [By Ben Levisohn]

    During the early stages of a new innovation, interdependent architectures and integrated companies best optimize performance and functionality. This trend has played out in computing and handsets, and we see the same trend playing out in EVs. We find Tesla and BYD1 , by far, the most vertically integrated players in EVs, with huge scale advantages. In addition, LG Chem, Panasonic (PCRFY), Samsung SDI, BYD, and CATL are clear scale leaders in batteries (CATL is not publicly traded. All but Samsung SDI and BYD are not covered by Bernstein.).

  • [By SEEKINGALPHA.COM]

    SMMYY is a subsidiary of the Sumitomo Group. SMMYY is a major smelter and refiner of copper, nickel and gold in Japan, and has a 27.5% stake in the Ambatovy Nickel Project in Madagascar, along with Sherritt International and Korea Resources Corp. Feedstock for the refinery is nickel cobalt mixed sulphide from its Taganito and Coral Bay mines in the Philippines (noting the Philippines is a risky supply source at this time). Sumitomo supply Panasonic (OTCPK:PCRFY) who supply Tesla (NASDAQ:TSLA); however, this can change. Generally, I like the stock; however, at this time, valuation looks full, trading on a 2017 PE of 32.8, and 2018 PE of 14.8. Good to buy after a pullback if that occurs.

  • [By SEEKINGALPHA.COM]

    A Unilever vs. Panasonic (OTCPK:PCRFY) showdown seems to be something out of an alternative, weird universe. But that’s exactly what has been happening in the Asia-Pacific region, where Unilever is now a major seller of air and water purification devices. The acquisitions of Qinyuan and Pureit water purifiers, as well as the acquisition of Sweden-based Blueair in 2016, reflects Unilever’s latest growth strategy of reducing exposure to low-growth brands in favor of greater investments in higher-growth products with strong social and environmental credentials.

Top Bank Stocks To Watch For 2018: Intercept Pharmaceuticals, Inc.(ICPT)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap liver biopharmaceutical stock Intercept Pharmaceuticals Inc (NASDAQ: ICPT) reportedQ2 2017 earnings before the market opened on Monday with both the top and bottom lines beating expectations plus the Companyreported that amid-stage clinical trial met its primary endpoint; but sharesended the day down13.26%. Intercept Pharmaceuticals recognized $30.4 million of net sales of Ocaliva for Q2 2017 versus $75k and a net loss of $86.6 million versus a net loss of $77.3 million. Ocaliva was approved by the U.S.FDA in May 2016 for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. As of June 30, 2017,the Companyhad cash, cash equivalents and investment securities available for sale of approximately $550.3 million versus$689.4 million as of December 31, 2016. The CEO commented:

  • [By Paul Ausick]

    Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) dropped more than 17% Friday to post a new 52-week low of $60.97 after closing Thursday at $73.70. The 52-week high is $172.75. Volume of more than 10 million shares traded was about 12 times the daily average. The FDA on Thursday issued a warning letter on the company’s liver disease treatment.

Top Bank Stocks To Watch For 2018: Realogy Holdings Corp.(RLGY)

Advisors’ Opinion:

  • [By Lisa Abramowicz]

    Drugstore chain Rite Aid Corp. (RAD) and residential property firm Realogy Corp. (RLGY) are two of the 283 junk-rated borrowers identified in March 2009 by Moodys Investors Service as being at the highest risk of default that have since sold bonds.

  • [By Monica Wolfe]

    Realogy Holdings (RLGY)

    Paulsons third largest holding goes to Realogy Holdings. The guru holds on to 12,957,700 shares, representing 4.4% of his total portfolio and 8.87% of the companys shares outstanding.

  • [By Chad Tracy]

    Investments in Claire's retail stores, Realogy Holdings (NYSE: RLGY), and Harrah's Entertainment all came under pressure as the global credit crisis hit. Apollo was forced to shut off cash interest payments to investors and to issue more debt.  

Top Bank Stocks To Watch For 2018: Neptune Technologies & Bioresources Inc(NEPT)

Advisors’ Opinion:

  • [By Monica Gerson]

    Neptune Technologies & Bioressources (NASDAQ: NEPT) is projected to post a quarterly loss at $0.01 per share on revenue of $9.70 million.

    Apigee Corp (NASDAQ: APIC) is expected to post a quarterly loss at $0.27 per share on revenue of $23.17 million.

  • [By Jim Robertson]

    Yesterday, our Under the Radar Movers newsletter suggested small cap functional ingredient stock Neptune Technologies & Bioressources (NASDAQ: NEPT) as a long/bullish trade:

Top Bank Stocks To Watch For 2018: Trevena, Inc.(TRVN)

Advisors’ Opinion:

  • [By Lisa Levin]

    Trevena Inc (NASDAQ: TRVN) shares dropped 36 percent to $4.55 despite a positive development in Phase 3 trials. Trevena announced positive top-line results from ongoing Phase 3 trials called "APOLLO-1" and "APOLLO-2." The studies evaluated the safety of Trevena's oliceridine therapy in patients for 48 hours following bunionectomy and 24 hours following abdominoplasty.

  • [By Chris Lange]

    Trevena Inc. (NASDAQ: TRVN) reported positive results from two late-stage clinical trials that work to treat post-surgical pain. The company intends to submit these results to the FDA for a marketing approval agreement in the fourth quarter. Previously, oliceridine was approved for a breakthrough designation by the agency.

  • [By Maxx Chatsko]

    Shares of clinical-stage biopharma Trevena (NASDAQ:TRVN) fell nearly 12% today after it reported full-year 2016 earnings. The pre-revenue company didn’t announce any surprises one way or the other. However, investors appear to be considering the near-term consequences of swelling expenses that won’t be offset by product sales anytime soon.

  • [By Paul Ausick]

    Trevena Inc. (NASDAQ: TRVN) dropped about 6.3% Thursday, to post a new 52-week low of $3.70 after closing at $3.95 on Wednesday. The stock’s 52-week high is $9.73. Volume was nearly 5 times the daily average of around 700,000 shares. The company’s pain-killing drug got mixed results in a trial result reported Tuesday.

Best High Tech Stocks To Buy Right Now

On January 26, microprocessor giant Intel (NASDAQ:INTC) will report its financial results and provide financial guidance for the coming quarter and, likely, the entirety of 2017.

Although the company is planning to host its financial analyst day shortly thereafter, on February 9, during which the company will go into deeper dives into each of its business units, there are still several questions I’d like to hear answered during the company’s upcoming earnings call. Here are three.

Will the memory business be profitable this year?

Over the course of 2016, Intel’s non-volatile memory business — which builds and sells products based mainly on NAND flash and will soon begin shipping products based on its 3D XPoint technology — has lost a bunch of money.

A NAND flash-based solid-state drive. Image source: Intel.

The losses Intel has racked up here during the first three quarters of 2016 are $453 million, with more losses likely on the way during the fourth quarter.

Best High Tech Stocks To Buy Right Now: Alphatec Holdings, Inc.(ATEC)

Advisors’ Opinion:

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha)
    Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha)
    Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period.
    Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share.
    Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement.
    Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share.
    Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76.
    QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share.
    Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering.
    Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston
  • [By Lisa Levin]

    Shares of Alphatec Holdings Inc (NASDAQ: ATEC) were down around 25 percent to $2.00 as the company reported an $18.9 million private placement.

    Heat Biologics Inc (NASDAQ: HTBX) was down, falling around 15 percent to $0.872. Heat Biologics priced its 5 million share offering at $0.80 per share.

Best High Tech Stocks To Buy Right Now: BioAmber Inc.(BIOA)

Advisors’ Opinion:

  • [By Paul Ausick]

    BioAmber Inc. (NYSE: BIOA) dropped nearly 29% Friday to post a new 52-week low of $2.24 after closing Thursday at $3.14. Volume of more than 1.5 million shares was about 6 times the daily average of around 240,000. The company’s annual report, filed on Thursday with its quarterly results, included a “going concern” statement from the company’s independent auditing firm.

  • [By Markus Aarnio]

    BioAmber (BIOA) is a sustainable chemicals company. Its proprietary technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstock into chemicals for use in a wide variety of everyday products including plastics, resins, food additives and personal care products.

  • [By Lisa Levin]

    Bioamber Inc (NYSE: BIOA) shares dropped 19 percent to $2.55. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.

  • [By Lisa Levin] Related CRMD Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher 12 Biggest Mid-Day Gainers For Tuesday CorMedix's (CRMD) CEO Khoso Baluch on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related BIOA Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates BioAmber (BIOA) Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    CorMedix Inc. (NYSE: CRMD) shares fell 27.5 percent to $1.50 after the company reported Q4 results and issued a business update.
    Bioamber Inc (NYSE: BIOA) shares tumbled 23.6 percent to $2.40. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.
    The Medicines Company (NASDAQ: MDCO) shares dipped 20.9 percent to $41.62.
    Innocoll Holdings PLC (NASDAQ: INNL) shares fell 20.3 percent to $1.49. Innocoll posted a narrower-than-expected quarter loss, but revenue missed estimates. Stifel Nicolaus downgraded Innocoll from Buy to Hold.
    Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares declined 20.3 percent to $3.83. On Thursday, Rosetta Genomics disclosed a 1-for-12 reverse stock split.
    Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 19.9 percent to $23.76. Esperion Therapeutics shares have jumped 106.19 percent over the past 52 weeks, while the S&P 500 index has gained 16.70 percent in the same period.
    AmTrust Financial Services Inc (NASDAQ: AFSI) tumbled 18.3 percent to $17.65. AmTrust Financial disclosed that it will delay its annual report filing for the fiscal year ended December 31, 2016.
    Qualstar Corporation (NASDAQ: QBAK) slipped 17.7 percent to $6.85. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 milli

Best High Tech Stocks To Buy Right Now: Greenlight Capital Re Ltd.(GLRE)

Advisors’ Opinion:

  • [By Jim Robertson]

    Note that hedge fund mogul David Einhorn has been a director ofthe predecessor company since May 2006. Mr. Einhorn co-founded, and has served as the President of, Greenlight Capital, Inc., since January 1996. Funds managed by Greenlight are some ofthe Companys principal stockholders. Since July 2004, Mr. Einhorn has served as Chairman of the Board of Greenlight Capital Re, Ltd (Nasdaq: GLRE).

Best High Tech Stocks To Buy Right Now: Ormat Technologies, Inc.(ORA)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows shares of U.S. Geothermal back in positive territory while potential peer mid cap Calpine Corporation (NYSE: CPN) is underperforming and Ormat Technologies, Inc (NYSE: ORA) has been taking off for two years:

Best High Tech Stocks To Buy Right Now: Piedmont Natural Gas Company Inc.(PNY)

Advisors’ Opinion:

  • [By WWW.KIPLINGER.COM]

    Duke also recently has expanded on its natural gas efforts, and will add numerous more natural gas customers when its buy-out of Piedmont Natural Gas Company, Inc. (PNY) goes through.

Top Casino Stocks To Buy Right Now

Related MPEL Macau Records Largest Monthly Revenue Growth In Nearly 3 Years Is Monthly Gaming Win Data Still A Viable Trading Opportunity? Macau posts best monthly revenue growth since early 2014 (Seeking Alpha)
Related WYNN Macau Records Largest Monthly Revenue Growth In Nearly 3 Years Is Monthly Gaming Win Data Still A Viable Trading Opportunity? Macau posts best monthly revenue growth since early 2014 (Seeking Alpha)

Casino investors are taking profits on Thursday following positive monthly gaming revenue numbers from both Las Vegas and Macau. The numbers out of both gaming hubs confirm that strong underlying revenue growth is behind gambling stocks’ recent outperformance.

Top Casino Stocks To Buy Right Now: ENERGY TRANSFER PARTNERS(ETP)

Advisors’ Opinion:

  • [By Laurie Kulikowski]

    Despite any intermediate fluctuations, we have only bad news to report on this stock’s performance over the last year: it has tumbled by 46.65%, worse than the S&P 500’s performance. Consistent with the plunge in the stock price, the company’s earnings per share are down 77.27% compared to the year-earlier quarter. Although its share price is down sharply from a year ago, do not assume that it can now be tagged as cheap and attractive. The reality is that, based on its current price in relation to its earnings, ETP is still more expensive than most of the other companies in its industry.

     

  • [By Matthew DiLallo]

    Meanwhile, a noteworthy project in the midstream segment finally finished construction in the quarter, after the company and its joint venture partners Energy Transfer Partners (NYSE:ETP) and Sunoco Logistics Partners (NYSE:SXL)completed the controversial Dakota Access Pipeline and Energy Transfer Crude Oil Pipeline. The partners expect commercial operations to begin this June, which means that this pipeline should drive incremental earnings for Phillips 66 in the back half of this year.

  • [By Laurie Kulikowski]

    Double digit distribution secure, market underappreciates ETE support. We believe ETP has outlined a clear path to funding needed through YE16, after which ETP should start to realize the benefit of the ~$10bn of projects under construction. The ~$2.2bn drop down to SUN announced at the recent Analyst Day pre-funds nearly 70% of planned 2016 equity needs, with the potential for non-core asset sales and/or IDR waivers on future equity issuance to cover the balance. ETE’s growth depends upon a strong ETP, and we believe ETE will do what it takes to defend ETP. 

  • [By Laurie Kulikowski]

    Along with the very weak revenue results, ETP underperformed when compared to the industry average of 36.8%. Since the same quarter one year prior, revenues plummeted by 55.8%. Weakness in the company’s revenue seems to have hurt the bottom line, decreasing earnings per share.

     

  • [By Craig Jones]

    Enterprise Products Partners L.P. (NYSE: EPD) has a too high yield, and Cramer thinks that it is a bargain. He added that the problem is in Energy Transfer Partners LP (NYSE: ETP), which is pulling the whole group down.

  • [By Laurie Kulikowski]

    The debt-to-equity ratio of 1.30 is relatively high when compared with the industry average, suggesting a need for better debt level management. Along with the unfavorable debt-to-equity ratio, ETP maintains a poor quick ratio of 0.86, which illustrates the inability to avoid short-term cash problems.

     

Top Casino Stocks To Buy Right Now: The Hackett Group Inc.(HCKT)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Wednesday, industrial shares were relative laggards, down on the day by about 0.20 percent. Meanwhile, top losers in the sector included The Hackett Group, Inc. (NASDAQ: HCKT), down 22 percent, and PC Tel Inc (NASDAQ: PCTI), down 18 percent.

Top Casino Stocks To Buy Right Now: Alphatec Holdings, Inc.(ATEC)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Alphatec Holdings Inc (NASDAQ: ATEC) were down around 25 percent to $2.00 as the company reported an $18.9 million private placement.

    Heat Biologics Inc (NASDAQ: HTBX) was down, falling around 15 percent to $0.872. Heat Biologics priced its 5 million share offering at $0.80 per share.

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha)
    Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha)
    Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period.
    Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share.
    Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement.
    Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share.
    Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76.
    QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share.
    Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering.
    Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston

Top Casino Stocks To Buy Right Now: Geopark Ltd(GPRK)

Advisors’ Opinion:

  • [By Dustin Parrett]

    As a service to our readers, we’ve put together a list of 10 cheap oil stocks under $5. Here are the stocks, share prices, and year-to-date (YTD) returns for each:

    Vallourec Sp (OTCMKTS ADR: VLOWY); $1.42; +13.6% YTDIthaca Energy Inc. (TSE: IAE); $1.93; +14.5% YTDSandRidge Permian Trust (NYSE: PER); $3.45; +16.95% YTDGeopark Ltd. (NYSE: GPRK); $5.06; +17.4% YTDGastar Exploration Inc. (NYSEMKT: GST); $1.89; +22.26% YTDAscent Resources Plc. (LON: AST); $2.11; +25.53% YTDErin Energy Corp. (NYSEMKT: ERN); $3.94; +29.1% YTDChesapeake Granite Wash Trust (NYSE: CHKR); $3.25; +38.3% YTDSouthcross Energy Partners LP (NYSE: SXE); $2.27; +68.15% YTDBonanza Creek Energy Inc. (NYSE: BCEI); $2.27; +122.55% YTD

    This list of oil stocks contains some highly speculative plays, so we can’t recommend buying them.